Product Description
A-85380 [3-(2(s)-azetidinylmethoxy) pyridine] is a neuronal nicotinic acetylcholine receptor (nAChR) agonist that has been a useful tool in the investigation of the function of nAChRs in both preclinical and clinical studies. Amongst nAChR subtypes, A-85380 shows selectivity for the alpha(4)beta(2) vs. the alpha(7) or alpha(1)beta(1)deltagamma nAChRs. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/16958984/)
Mechanisms of Action: nAChR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: Europe
Company Founding Year: 1999
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Other
Phase 1: Alzheimer Disease|Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03268369 |
NICOPET | N/A |
Completed |
Epilepsy |
2015-11-01 |
2019-03-21 |
Treatments |
|
NCT00039702 |
02-M-0058 | N/A |
Completed |
Alzheimer Disease |
None |
2019-03-21 |
Treatments |
|
NCT00886067 |
D1950C00004 | P1 |
Completed |
Healthy Volunteers |
2009-08-01 |
2025-08-27 |
Primary Endpoints|Treatments |
|
NCT00686413 |
PET | P1 |
Completed |
Alzheimer Disease |
2008-08-01 |
2019-03-18 |
Treatments |
|
2007-004979-19 |
Nicotinic-PET in neurodegenerative diseases | P2 |
Completed |
Other |
2016-11-01 |
2022-03-12 |
Treatments |